Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase III and, if approved, would be the… Read More
The US Food and Drug Administration (FDA) has approved the first and only therapy for Menkes disease. Zycubo (copper histidinate), developed by US biopharmaceutical company Sentynl Therapeutics, is a subcutaneous injectable formulation given daily to deliver elemental copper to the body. In a pooled analysis of two… Read More
Biopharmaceutical company Sentynl Therapeutics has acquired Eiger Biopharmaceuticals’ approved treatment for the rare disease progeria. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in young people 12 months of age and older, are ultra-rare, fatal, genetic premature ageing diseases that accelerate mortality… Read More
